This study is evaluating whether vididencel can help patients being treated for AML with standard-of-care low-intensity therapy stay in remission for longer.

The Olivia Newton-John Cancer Research Institute (ONJCRI) is delighted to announce the launch of the DIVA Phase 1b clinical trial. This new study is evaluating whether vididencel can help patients being treated for acute myeloid leukaemia (AML) with standard-of-care low-intensity therapy stay in remission for longer.

Vididencel is a dendritic cell immunotherapy already in clinical trials for a number of cancers.  Rather than targeting the cancer cells directly, vididencel works by boosting the body’s natural immune defences, with the goal of preventing relapse thereby extending periods of remission.

AML is an aggressive blood cancer diagnosed in 1200 Australians each year, including children and adults, with a 5-year survival rate of 27%. The Leukaemia Foundation describes AML as an under-invested rare cancer.

Even after treatment, a small number of leukaemia cells can persist and cause AML to return later.  These cells are hard to eliminate with standard treatment alone. However, the immune system may be able to identify and flag these cells for immune destruction, which is why boosting the immune system with immunotherapy could be an effective strategy to prevent AML relapse.

The DIVA trial is focusing on whether vididencel can help the body’s own immune system clear out these leftover cells in newly diagnosed AML patients who have responded to initial standard low-intensity therapy.

The DIVA trial (Phase 1b, single-arm) will recruit 24 participants across 4 sites in Victoria. The trial is led by Professor Andrew Wei (Peter MacCallum Cancer Centre), Dr Stephen Ma (WEHI) and coordinated by ONJCRI’s Clinical Trials Unit.

Importantly, this trial broadens the potential reach of vididencel to include newly diagnosed patients considered unfit for intensive chemotherapy and allogeneic stem cell transplantation, a population in real need of new options.

We are proud to undertake this work and look forward to collaborating with Mendus to improve outcomes for AML patients.

Privacy Preference Center